|
NEK9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.93741999999775E-05 |
| Normal-vs-Stage3 |
6.66133814775094E-16 |
| Normal-vs-Stage4 |
1.63935531816151E-12 |
| Stage1-vs-Stage2 |
9.599500E-02 |
| Stage1-vs-Stage3 |
5.443600E-02 |
| Stage1-vs-Stage4 |
4.799600E-02 |
| Stage2-vs-Stage3 |
5.802100E-03 |
| Stage2-vs-Stage4 |
5.638500E-03 |
| Stage3-vs-Stage4 |
6.850400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.93669999995583E-06 |
| Normal-vs-Asian |
6.85909995468137E-10 |
| Caucasian-vs-AfricanAmerican |
3.252800E-01 |
| Caucasian-vs-Asian |
3.051600E-01 |
| AfricanAmerican-vs-Asian |
8.288400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.65041330496751E-13 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.226200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
3.0364599723498E-13 |
| Normal-vs-Age(61-80Yrs) |
1.91391347215131E-12 |
| Normal-vs-Age(81-100Yrs) |
1.97266999999446E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.693800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.324600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.187600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.957000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.022400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.917200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.0151999999829E-06 |
| Classical-VS-Follicular |
4.249400E-01 |
| Classical-VS-Other |
9.727400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.61529999999077E-05 |
| Tall-VS-Other |
2.625800E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
7.809400E-01 |
| Follicular-VS-Normal |
1.43959999476806E-08 |
| Other-VS-Normal |
2.099000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.67323965583455E-14 |
| Normal-vs-N1 |
1.28674848554056E-13 |
| N0-vs-N1 |
5.631600E-02 |
|
|
